S. Karger AG

SHERPA: Unknown

People

  1. Bodei
    Bodei
  2. Drilon
    Drilon
  3. Motzer
    Motzer
  4. Abou-Alfa
    Abou-Alfa
  5. Chaganti
    Chaganti
  6. Lin
    Lin
  7. Janjigian
    Janjigian
  8. Jhanwar
    Jhanwar
  9. Tang
    Tang
  10. Clarkson
    Clarkson

Groups

  1. Department of Medicine (280)
  2. Solid Tumor Oncology Division (160)
  3. Hematologic Malignancies, Division of (107)
  4. Center for Hematologic Malignancies (103)
  5. Survivorship Research (59)
  6. Gastrointestinal Oncology Service (57)
  7. Sloan Kettering Institute Postdocs (55)
  8. Surgery (54)
  9. Thoracic Oncology (45)
  10. Department of Pathology and Laboratory Medicine (43)
Search Within
Formats
  1. Meeting Abstract (332)
  2. Journal Article (255)
  3. Book Section (20)
  4. Review (16)
  5. Conference Paper (10)
  6. Book Whole (1)
  7. Editorial (1)
Groups
  1. Department of Medicine (280)
  2. Solid Tumor Oncology Division (160)
  3. Hematologic Malignancies, Division of (107)
  4. Center for Hematologic Malignancies (103)
  5. Survivorship Research (59)
  6. Gastrointestinal Oncology Service (57)

More Groups

People
  1. Lisa Bodei (32)
  2. Alexander Drilon (23)
  3. Robert Motzer (23)
  4. Ghassan Abou-Alfa (18)
  5. Steven Hajdu (18)
  6. Oscar Lin (16)

More People

Years
  1. 2025 (5)
  2. 2024 (21)
  3. 2023 (37)
  4. 2022 (42)
  5. 2021 (31)
  6. 2020 (51)

More Years

Publications
  1. Oncology Research and Treatment (226)
  2. Cytogenetics and Cell Genetics (61)
  3. Acta Cytologica (58)
  4. Neuroendocrinology (51)
  5. Acta Haematologica (32)
  6. Onkologie (19)

More Publications

Results (635)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Illustrating cancer risk: Patient risk communication preferences and interest regarding a novel BRCA1/2 genetic risk modifier test
    Journal Article

    Hamilton, J. G.; Genoff Garzon, M.; Shah, I. H.; Cadet, K.; Shuk, E.; Westerman, J. S.; Hay, J. L.; Offit, K.; Robson, M. E.
    Public Health Genomics (2020)

    Fulltext@MSK | Save
  • The use of deep learning and neural networks in imaging: welcome to the new mathematical milieu of medicine
    Editorial

    Modlin, I. M.; Kidd, M.; Drozdov, I. A.; Bodei, L.
    Neuroendocrinology (2020)

    Fulltext@MSK | Save
  • Integrative genomic characterization identifies molecular subtypes of lung carcinoids
    Meeting Abstract

    Laddha, S. V.; da Silva, E. M.; Robzyk, K.; Untch, B. R.; Ke, H.; Rekhtman, N.; Poirier, J. T.; Travis, W. D.; Tang, L. H.; Chan, C. S.
    Neuroendocrinology (2020)

    Fulltext@MSK | Save
  • PRRT neuroendocrine tumor response assessment using circulating transcript analysis: The NETest
    Meeting Abstract

    Bodei, L.; Kidd, M.; Singh, A.; van der Zwan, V.; Severi, S.; Drozdov, I.; Malczewska, A.; Baum, R. P.; Kwekkeboom, D.; Paganelli, G.; more...
    Neuroendocrinology (2020)

    Fulltext@MSK | Save
  • A meta-analysis of the accuracy of a neuroendocrine tumor mRNA genomic biomarker (NETest) in blood
    Meeting Abstract

    Oberg, K.; Califano, A.; Strosberg, J.; Ma, S.; Pape, U. F.; Bodei, L.; Kaltsas, G.; Toumpanakis, C.; Goldenring, J.; Frilling, A.; more...
    Neuroendocrinology (2020)

    Fulltext@MSK | Save
  • Nivolumab (N) plus low-dose ipilimumab (I) vs platinum-doublet chemotherapy (Chemo) as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (NSCLC): Checkmate 227 part 1 final analysis
    Meeting Abstract

    Reck, M.; Peters, S.; Ramalingam, S.; Paz-Ares, L.; Caro, R. B.; Zurawski, B.; Kim, S. W.; Alexandru, A.; Lupinacci, L.; Jitnenez, E. D.; more...
    Oncology Research and Treatment (2020)

    Fulltext@MSK | Save
  • Entrectinib in patients with NTRK fusion-positive solid tumors or ROS1-positive NSCLC with CNS metastases
    Meeting Abstract

    Paz-Ares, L.; Dziadziuszko, R.; Drilon, A.; John, T.; Krebs, M.; Demetri, G.; Shaw, A. T.; Siena, S.; Wolf, J.; Farago, A. F.; more...
    Oncology Research and Treatment (2020)

    Fulltext@MSK | Save
  • Entrectinib in locally advanced / metastatic ROS1 and NTRK fusion-positive (NTRK plus ) non-small cell lung cancer (NSCLC): Updated integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001
    Meeting Abstract

    Springfeld, C.; de Braude, F.; Siena, S.; Barlesi, F.; Drilon, A.; Simmons, B.; Huang, X.; Pitcher, B.; Doebele, R. C.
    Oncology Research and Treatment (2020)

    Fulltext@MSK | Save
  • Safety and efficacy results from Transcend NHL 001, a multicenter phase 1 study of lisocabtagene maraleucel (liso-cel) In relapsed/refractory (R/R) large B-cell lymphoma (LBCL)
    Meeting Abstract

    Abramson, J.; Palomba, M. L.; Gordon, L.; Lunning, M.; Wang, M.; Arnason, J.; Mehta, A.; Purev, E.; Maloney, D.; Andreadis, C.; more...
    Oncology Research and Treatment (2020)

    Fulltext@MSK | Save
  • Genomic landscape of entrectinib resistance from circulating tumor DNA (CTDNA) analysis in STARTRK-2
    Meeting Abstract

    Doebele, R. C.; Dziadziuszko, R.; Drilon, A.; Shaw, A. T.; Wolf, J.; Farago, A. F.; Dennis, L.; Riehl, T.; Simmons, B.; Wu, C.; more...
    Oncology Research and Treatment (2020)

    Fulltext@MSK | Save